Biological basis for chemo-radiotherapy interactions

European Journal of Cancer

Volumn 38, Issue 2, 2002, Pages 223-230

  Hennequin, C ^a   Favaudon, V ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Chemo radiotherapy; Gemcitabine; Taxane

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLOXURIDINE; GEMCITABINE; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER TISSUE; CELL CYCLE; CELL KINETICS; CELL SYNCHRONIZATION; CLINICAL TRIAL; CYTOKINESIS; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DRUG MECHANISM; DRUG SENSITIVITY; DRUG UPTAKE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RADIOSENSITIVITY; RADIOSENSITIZATION; REOXYGENATION; TARGET ORGAN; TISSUE SPECIFICITY; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DNA ADDUCTS; DNA REPAIR; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; RADIOTHERAPY; TAXOIDS;

EID: 0036167369     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00360-4     Document Type: Article

References (96)

1. Terminology in the description of drug-radiation interactions
2. The search for therapeutic gain in the combination of radiotherapy and chemotherapy
3. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
4. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
5. Repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide
6. Radiation-induced DNA double-strand breaks and the radiosensitivity of human cells: A closer look
7. Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionising radiation
8. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease
9. The role of DNA mismatch repair in drug resistance
10. Cisplatin and radiation: Interaction probabilities and therapeutic possibilities
11. Production of DNA double-strand breaks by interactions between carboplatin and radiation: A potential mechanism for radiopotentiation
12. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction
13. Localization of topoisomerase II in mitotic chromosomes
14. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells
15. DNA topoisomerase II cleavage of telomeres in vitro and in vivo
16. Radiation-induced arrest of cells in G2 phase elicits hypersensitivity to DNA double-strand break inducers and an altered pattern of DNA cleavage upon re-irradiation
17. Biphasic survival curves for XRS radiosensitive cells: Subpopulations or transient expression of repair competence?
18. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line
19. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin
20. Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells
21. Wortmannin inhibits repair of DNA double-strand breaks in irradiated normal human cells
22. Fluorouracil: Biochemistry and pharmacology
23. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects
24. Radiosensitizing nucleosides
25. Radiosensitization by fluorodeoxyuridine: Effects of thymidylate synthase inhibition and cell synchronization
26. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
27. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
28. Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma
29. The effect of 2′,2′-difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
30. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells
31. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine)
32. Kinetics of mouse jejunum radiosensitization by 2′,2′-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells
33. Gemcitabine-mediated radiosensitization
34. Gemzar® (gemcitabine) with thoracic radiotherapy: A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
35. Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iodo-deoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity
36. Kinetische Untersuchungen zur Gamma-Radiolyse von 5-Bromouracil in wässriger Lösung
37. Pulse-radiolysis and flash-photolysis study of aqueous solutions of simple pyrimidines. Uracil and bromouracil
38. Intermediates in the reduction of 5-halouracils by hydrated electrons
39. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine
40. Variations in several responses of HeLa cells to X-irradiation during the division cycle
41. X-Ray sensitivity during the cell generation cycle of cultured Chinese hamster cells
42. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and Hela cells
43. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)
44. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells
45. Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive
46. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells
47. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase
48. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines
49. Taxol stabilizes microtubules in mouse fibroblast cells
50. Taxol binds to polymerized tubulin in vitro
51. Relationships between the structure of taxol analogues and their antimitotic activity
52. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition
53. Substoichiometric binding of taxol suppresses microtubule dynamics
54. How does taxol stabilize microtubules?
55. Development of polyploidization in taxol-resistant human leukemia cells in vitro
56. Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells
57. Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis
58. Taxol sensitizes human astrocytoma cells to radiation
59. Radiation sensitizing effects of taxotere (RP 56976)
60. Taxol sensitizes human ovarian cancer cells to radiation
61. Taxol and ionizing radiation: Interaction and mechanisms
62. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol)
63. Radiation and taxol effects on synchronized human cervical carcinoma cells
64. Taxol in combination with acute and low dose rate irradiation
65. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines
66. Interaction of Ionizing radiation with Paclitaxel and Docetaxel in HeLa and SQ20B cells
67. Investigation of taxol as a potential radiation sensitizer
68. Subadditive interaction of radiation and Taxol in vitro
69. S-phase specificity of cell killing by docetaxel (taxotere) in synchronised HeLa cells
70. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo
71. Cell synchronization unfortunately may not benefit cancer therapy
72. Relationship of mitotic arret and apoptosis to antitumor effect of paclitaxel
73. Radiation-induced centrosome overduplication and multiple mitotic spindles in human tumor cells
74. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells
75. Apoptosis: Molecular regulation of cell death
76. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
77. Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation
78. The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization
79. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel
80. Maximizing therapeutic gain with gemcitabine and fractionated radiation
81. Irradiation enhances cellular uptake of Carboplatin
82. 5-Fluorouracil uptake by irradiation perturbed tumor
83. Loss of local control with prolongation in radiotherapy
84. What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation?
85. The EGF receptor family as targets for cancer therapy
86. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
87. Physical interactions between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells
88. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
89. Combined effects of angiostatin and ionizing radiation in antitumour therapy
90. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts
91. Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer
92. Radiosensitization of mouse breast cancer cells in vitro by estramustine
93. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three dimensional conformal radiotherapy for patients with locally advanced prostate cancer
94. Pharmocologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X-rays
95. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery